Interview with Montel Williams and Cannabis Science Conference’s Josh Crossney on The Cannabis Reporter’s 100th Episode hosted by Snowden Bishop
Study: Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction
The aim of this retrospective study was to quantify short-term outcomes in marijuana-using and non-using patients hospitalized with AMI.
According to the study authors, cannabis users are significantly less likely to die folling an acute myocardial infarction than non-cannabis users
Josh Crossney, founder of the nonprofit advocacy, JCanna, explains how he is bringing the science of cannabis into public awareness through his annual Cannabis Science Conference
Verax Research has secured investment and infrastructure Intellectual Property licenses from three companies to facilitate, compile and integrate advanced service offering available globally for its healthcare product manufacturer clients developing cannabis products.
Study Shows Sharp Decline of Opiates Dispensed to Medicaid Recipients In States Regulating Medical Marijuana
New study published in the Journal of the American Medical Association finds a sharp decline of opiate doses dispensed to Medicaid recipients annually in regulation states
New study concludes that opiates dispensed to Medicare Part D subscribers dropped by an average of 3.6% or 3.742 million daily doses per year on average.
Researchers conducting a study on cannabis as a treatment for PTSD are seeking U.S. Military veterans to participate in a controlled clinical trial.
Genome scientist Dr. Rahul Kushwah & cannabis expert Mike Heart, M.D. explain why genetic testing helps doctors understand how cannabis effects patients.
St George’s, University of London Department of Oncology shows evidence that cannabinoids kill leukemia cells when combined with chemotherapy.
New study conducted by Dr. Saul Garza Morales of Mexico concludes with results showing effectiveness of RSHO-X CBD treating childhood epilepsy.
As the first comprehensive study to be conducted by a Federally sanctioned institution, the NAS study has potential to expose the fallacy of the classification of cannabis as a Schedule 1 controlled substance.